Dendreon, still trying to claw its way back to financial security, has found a buyer for its Provenge manufacturing plant in New Jersey. Novartis has agreed to buy the facility for $43 million and take on 100 of its employees.
Roche's decision to shut down its longtime U.S. hub in Nutley, NJ, is causing some serious heartache there.
Roche's decision to shutter its big R&D complex in Nutley, NJ, is causing some serious heartache in the state, which has long been known as the home to a wide variety of biopharma companies.
Allergan has ambitious plans to swell its ranks with the opening of a new R&D facility in the Garden State. The news comes amid a major push at Allergan to expand the use of Botox far beyond fixing facial wrinkles and to develop therapies for a variety of ailments.
The news last week that Sanofi ( $SNY ) is reconfiguring its U.S. R&D operations in New Jersey and Massachusetts could be a harbinger of deep cuts for its European arena. The U.K.'s Business Weekly
A New Jersey appellate court may have just negated more than 150 lawsuits over hormone replacement therapy. The panel ruled last week that Pfizer ( $PFE ) can't be sued by two women who claim that HRT
Novo Nordisk is planning to renovate an old Merrill Lynch facility in New Jersey, making it into a new U.S. headquarters campus as it expands with hundreds of corporate and clinical development
New Jersey is building talent networks around seven industry sectors that are leading the state's economy. Among them: life sciences, advanced manufacturing, and logistics and distribution. Workforce
New Jersey officials, including Governor Chris Christie, have cheered Bayer HealthCare Pharmaceuticals' decision to consolidate operations in that state--a move that comes thanks in part to $35
Bayer HealthCare gave New Jersey a boost with its decision to consolidate East Coast operations there. The move will keep 1,000 jobs in the state and add up to 500 more, according to an announcement